ASX Stocks at 52 Weeks High
These companies are showing strong momentum with their recent announcements supporting business progress, growth plans and investor interest as their share prices trade at their 52 week highs.
Carnegie Clean Energy Limited (ASX: CCE)
Carnegie Clean Energy Limited (ASX: CCE) on 26 June 2026, announced that assembly of the CETO wave energy unit is progressing for the ACHIEVE Programme. Power take-off modules are being completed, with the first module sent to Germany for final assembly before returning to the Basque Country. Deployment, commissioning and testing are scheduled to begin in October 2026. Offshore installation and onshore testing will confirm the project-specific design and construction completed over the past three years.
On 15 May 2026, the company received a EuropeWave milestone payment of €63,688, about AUD103,000. The payment followed approval for deployment at the BiMEP site and completion of control software for upcoming power take-off testing, after required Spanish regulatory authorisations were secured.
On 7 May 2026, Carnegie was selected for US TEAMER technical support worth USD194,000, about AUD270,000, to develop offshore wave-powered energy solutions with Kelson Marine for fish pens.
Optiscan Imaging Limited (ASX: OIL)
Optiscan Imaging Limited (ASX: OIL), on 7 July 2026, launched the InSpecta veterinary imaging device in the United States after submitting its FDA dossier. Commercial sales have started, and the device is being presented at the AVMA Convention in Anaheim during 10–14 July 2026. This is the company’s first clinical product available in the U.S. market.
On 4 June 2026, Optiscan reached the halfway point in its breast cancer study with The Royal Melbourne Hospital. Twenty-five of 50 patients have been imaged, while recruitment has expanded to a second site. The study is evaluating InVue and InForm, with results planned for future U.S. FDA submissions.
On 1 June 2026, Optiscan marked two years of its Mayo Clinic agreement. Development of an imaging system for robotic surgery met planned engineering goals, and the agreement was extended until 12 August 2026 for further planning and development.
Mastermyne Group Limited (ASX: MYE),
Mastermyne Group Limited (ASX: MYE), on 20 May 2026, announced that FY26 revenue and underlying EBITDA will be on the high side of their guidance range. Revenues from operations for the year to 30 April 2026 before auditing amounted to $193.3 million, with net cash of $36.9 million. Strong second half performance was driven by high strata consolidation activity, with mining operations continuing to perform well.
The company’s order book was $461 million as at 30 April 2026, including contract extension options of $178 million. Mastermyne also has a $1.3 billion pipeline of opportunities across mining services, strata consolidation and products, with $593 million considered near-term.
Mastermyne is focused on expanding work with existing clients, securing new projects and developing additional service offerings. MYE is also exploring strategic acquisitions that can extend its capabilities, locations or service areas while maintaining careful capital management.
(Source: Company Report)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
